1. Home
  2. ASMB vs ENTX Comparison

ASMB vs ENTX Comparison

Compare ASMB & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASMB
  • ENTX
  • Stock Information
  • Founded
  • ASMB 2005
  • ENTX 2010
  • Country
  • ASMB United States
  • ENTX Israel
  • Employees
  • ASMB N/A
  • ENTX N/A
  • Industry
  • ASMB Biotechnology: Pharmaceutical Preparations
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ASMB Health Care
  • ENTX Health Care
  • Exchange
  • ASMB Nasdaq
  • ENTX Nasdaq
  • Market Cap
  • ASMB 92.1M
  • ENTX 90.2M
  • IPO Year
  • ASMB 2010
  • ENTX 2018
  • Fundamental
  • Price
  • ASMB $13.42
  • ENTX $2.55
  • Analyst Decision
  • ASMB Buy
  • ENTX Strong Buy
  • Analyst Count
  • ASMB 2
  • ENTX 1
  • Target Price
  • ASMB $35.00
  • ENTX $10.00
  • AVG Volume (30 Days)
  • ASMB 22.6K
  • ENTX 86.5K
  • Earning Date
  • ASMB 03-27-2025
  • ENTX 03-07-2025
  • Dividend Yield
  • ASMB N/A
  • ENTX N/A
  • EPS Growth
  • ASMB N/A
  • ENTX N/A
  • EPS
  • ASMB N/A
  • ENTX N/A
  • Revenue
  • ASMB $28,326,000.00
  • ENTX $99,000.00
  • Revenue This Year
  • ASMB $282.16
  • ENTX N/A
  • Revenue Next Year
  • ASMB N/A
  • ENTX N/A
  • P/E Ratio
  • ASMB N/A
  • ENTX N/A
  • Revenue Growth
  • ASMB N/A
  • ENTX 607.14
  • 52 Week Low
  • ASMB $9.84
  • ENTX $0.71
  • 52 Week High
  • ASMB $19.93
  • ENTX $3.35
  • Technical
  • Relative Strength Index (RSI)
  • ASMB 40.25
  • ENTX 61.93
  • Support Level
  • ASMB $13.60
  • ENTX $2.00
  • Resistance Level
  • ASMB $14.25
  • ENTX $2.62
  • Average True Range (ATR)
  • ASMB 0.58
  • ENTX 0.18
  • MACD
  • ASMB -0.05
  • ENTX 0.01
  • Stochastic Oscillator
  • ASMB 5.93
  • ENTX 96.77

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Share on Social Networks: